Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.23
XRAY's Cash-to-Debt is ranked lower than
88% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. XRAY: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
XRAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.08 Max: No Debt
Current: 0.23
Equity-to-Asset 0.67
XRAY's Equity-to-Asset is ranked higher than
61% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. XRAY: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
XRAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.52 Max: 0.8
Current: 0.67
0.22
0.8
Debt-to-Equity 0.22
XRAY's Debt-to-Equity is ranked higher than
60% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. XRAY: 0.22 )
Ranked among companies with meaningful Debt-to-Equity only.
XRAY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.44 Max: 2.19
Current: 0.22
0.07
2.19
Debt-to-EBITDA -3.95
XRAY's Debt-to-EBITDA is ranked lower than
99.99% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. XRAY: -3.95 )
Ranked among companies with meaningful Debt-to-EBITDA only.
XRAY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.95  Med: 2.11 Max: 4.59
Current: -3.95
-3.95
4.59
Piotroski F-Score: 5
Altman Z-Score: 3.13
Beneish M-Score: -3.07
WACC vs ROIC
10.15%
-8.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -18.51
XRAY's Operating Margin % is ranked lower than
75% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. XRAY: -18.51 )
Ranked among companies with meaningful Operating Margin % only.
XRAY' s Operating Margin % Range Over the Past 10 Years
Min: -18.51  Med: 14.73 Max: 17.66
Current: -18.51
-18.51
17.66
Net Margin % -20.33
XRAY's Net Margin % is ranked lower than
75% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. XRAY: -20.33 )
Ranked among companies with meaningful Net Margin % only.
XRAY' s Net Margin % Range Over the Past 10 Years
Min: -20.33  Med: 11.27 Max: 12.94
Current: -20.33
-20.33
12.94
ROE % -10.07
XRAY's ROE % is ranked lower than
70% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. XRAY: -10.07 )
Ranked among companies with meaningful ROE % only.
XRAY' s ROE % Range Over the Past 10 Years
Min: -10.07  Med: 13.89 Max: 18.61
Current: -10.07
-10.07
18.61
ROA % -6.92
XRAY's ROA % is ranked lower than
68% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. XRAY: -6.92 )
Ranked among companies with meaningful ROA % only.
XRAY' s ROA % Range Over the Past 10 Years
Min: -6.92  Med: 6.55 Max: 10.69
Current: -6.92
-6.92
10.69
ROC (Joel Greenblatt) % -46.12
XRAY's ROC (Joel Greenblatt) % is ranked lower than
77% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. XRAY: -46.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XRAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46.12  Med: 38.16 Max: 54.55
Current: -46.12
-46.12
54.55
3-Year Revenue Growth Rate -6.00
XRAY's 3-Year Revenue Growth Rate is ranked lower than
78% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. XRAY: -6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XRAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6  Med: 11.9 Max: 42.9
Current: -6
-6
42.9
3-Year EBITDA Growth Rate -3.60
XRAY's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. XRAY: -3.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XRAY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.4  Med: 9.5 Max: 50.5
Current: -3.6
-22.4
50.5
3-Year EPS without NRI Growth Rate -3.50
XRAY's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. XRAY: -3.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XRAY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.9  Med: 11 Max: 88.3
Current: -3.5
-32.9
88.3
GuruFocus has detected 4 Warning Signs with Dentsply Sirona Inc XRAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XRAY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

XRAY Guru Trades in Q4 2016

Pioneer Investments 877,100 sh (New)
Andreas Halvorsen 1,680,154 sh (+141.89%)
Jim Simons 301,858 sh (+67.27%)
Ruane Cunniff 9,102,714 sh (+11.51%)
Chuck Royce 75,900 sh (+10.00%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Mario Gabelli 121,210 sh (-3.27%)
Columbia Wanger 516,159 sh (-15.94%)
» More
Q1 2017

XRAY Guru Trades in Q1 2017

Steven Cohen 1,027,933 sh (New)
Jim Simons 1,044,558 sh (+246.04%)
Chuck Royce 102,650 sh (+35.24%)
Pioneer Investments 884,680 sh (+0.86%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ruane Cunniff 8,721,237 sh (-4.19%)
Mario Gabelli 114,210 sh (-5.78%)
Columbia Wanger 458,186 sh (-11.23%)
Andreas Halvorsen 854,398 sh (-49.15%)
» More
Q2 2017

XRAY Guru Trades in Q2 2017

Paul Tudor Jones 7,613 sh (New)
Joel Greenblatt 78,828 sh (New)
Andreas Halvorsen 1,430,369 sh (+67.41%)
Pioneer Investments 1,301,449 sh (+47.11%)
Chuck Royce 126,650 sh (+23.38%)
Ruane Cunniff 8,849,888 sh (+1.48%)
Mario Gabelli 114,210 sh (unchged)
Jim Simons Sold Out
Steven Cohen 946,100 sh (-7.96%)
Vanguard Health Care Fund 1,453,190 sh (-23.70%)
Columbia Wanger 294,726 sh (-35.68%)
» More
Q3 2017

XRAY Guru Trades in Q3 2017

Jerome Dodson 455,000 sh (New)
Paul Tudor Jones 37,205 sh (+388.70%)
Andreas Halvorsen 3,553,517 sh (+148.43%)
Steven Cohen 1,096,800 sh (+15.93%)
Ruane Cunniff 8,890,655 sh (+0.46%)
Steven Cohen 400,000 sh (unchged)
Vanguard Health Care Fund 1,453,190 sh (unchged)
Columbia Wanger Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 113,910 sh (-0.26%)
Chuck Royce 109,885 sh (-13.24%)
Pioneer Investments 448,135 sh (-65.57%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2017-09-30 Add 0.46%0.02%$52.79 - $65.11 $ 67.5513%8,890,655
Mario Gabelli 2017-09-30 Reduce -0.26%$52.79 - $65.11 $ 67.5513%113,910
Joel Greenblatt 2017-09-30 Sold Out 0.07%$52.79 - $65.11 $ 67.5513%0
Ruane Cunniff 2017-06-30 Add 1.48%0.08%$61.35 - $65.59 $ 67.557%8,849,888
Vanguard Health Care Fund 2017-06-30 Reduce -23.70%0.06%$61.35 - $65.59 $ 67.557%1,453,190
Joel Greenblatt 2017-06-30 New Buy0.07%$61.35 - $65.59 $ 67.557%78,828
Ruane Cunniff 2017-03-31 Reduce -4.19%0.21%$55.59 - $64.5 $ 67.5512%8,721,237
Mario Gabelli 2017-03-31 Reduce -5.78%$55.59 - $64.5 $ 67.5512%114,210
Ruane Cunniff 2016-12-31 Add 11.51%0.51%$55.83 - $61.19 $ 67.5514%9,102,714
Mario Gabelli 2016-12-31 Reduce -3.27%$55.83 - $61.19 $ 67.5514%121,210
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:TSE:4543, TSE:7733, NYSE:WAT, NYSE:RMD, NYSE:COO, XSWX:STMN, NYSE:MTD, NAS:HOLX, OCSE:COLO B, NYSE:STE, NYSE:WST, OSTO:GETI B, SZSE:002294, NYSE:HRC, NYSE:BCR, NYSE:CMD, NAS:ICUI, TSE:7747, NAS:PODD, MIL:AMP » details
Traded in other countries:XRAY.Austria, DY2.Germany,
Headquarter Location:USA
Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. It also manufactures and markets other consumable medical device products.

Dentsply Sirona is one of the world's largest manufacturers and distributors of dental supplies and equipment. Its product segments include dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. Over half of its products are sold through dental distributors, and approximately 65% of Dentsply's sales are outside the U.S.

Guru Investment Theses on Dentsply Sirona Inc

Jerome Dodson Comments on Dentsply Sirona - Oct 25, 2017

Dentsply Sirona (NASDAQ:XRAY) is the leading manufacturer of dental consumables and equipment. The stock sold off due to distribution problems involving fellow Parnassus Fund’s holding Patterson Companies. We believe these issues are temporary, so we used the weakness as an opportunity to add Dentsply Sirona to the portfolio at what we believe is an attractive valuation.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Ruane Cunniff Comments on Dentsply Sirona - Oct 13, 2016

After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of performance.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund third quarter 2016 letter to shareholders.

Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Dentsply Sirona Inc

Weekly Top Insider Buys Highlight for the Week of Nov. 17 The largest Insider Buys this week were for General Electric Co. (GE), Williams Companies Inc. (WMB), EQT Corp. (EQT), and Dentsply Sirona Inc. (XRAY).
The largest Insider Buys this week were for General Electric Co. (NYSE:GE), Williams Companies Inc. (NYSE:WMB), EQT Corp. (NYSE:EQT), and Dentsply Sirona Inc. (NASDAQ:XRAY). Read more...
Stock Market Opens Higher on Friday MercadoLibre rises on earnings beat
Wall Street indexes opened mostly higher Friday morning on the back of the Labor Department releasing its hiring and unemployment numbers for October, reporting the unemployment rate fell to 4.1% as labor conditions returned to normal following Hurricanes Harvey and Irma.  Read more...
Jerome Dodson Comments on Dentsply Sirona Guru stock highlight
Dentsply Sirona (NASDAQ:XRAY) is the leading manufacturer of dental consumables and equipment. The stock sold off due to distribution problems involving fellow Parnassus Fund’s holding Patterson Companies. We believe these issues are temporary, so we used the weakness as an opportunity to add Dentsply Sirona to the portfolio at what we believe is an attractive valuation.
Read more...
Dentsply Sirona to Report Third Quarter 2017 Results on November 3rd
Lifshitz & Miller LLP Announces Investigation of Antares Pharma, Inc., CenturyLink, Inc., CytRx Corporation, Dentsply Sirona, Inc., Dr. Reddy's Laboratories Limited, J.Jill, Inc., and Navient Corporation
Dentsply Sirona Announces Additions to Executive Leadership Team
Jerome Dodson Starts 5 New Positions in 3rd Quarter Guru reports quarterly portfolio
Parnassus Fund manager Jerome Dodson (Trades, Portfolio) seeks long-term capital appreciation through securities with the following characteristics: wide competitive advantages, good management quality and “relevancy over the long term.” Read more...
(XRAY) Alert: Johnson Fistel Investigates DENTSPLY SIRONA Inc. Following Resignation of Top Three Officers and SEC Investigation; Encourages Investors to Contact the Firm
Dentsply Sirona Investor Alert: Hagens Berman Alerts Dentsply Sirona, Inc. Investors to Investigation of Potential Securities Law Violations Connected to SEC Enforcement Inquiry and Management Shakeup
Dentsply Sirona Announces Leadership Changes

Ratios

vs
industry
vs
history
Forward PE Ratio 22.73
XRAY's Forward PE Ratio is ranked higher than
75% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. XRAY: 22.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.07
XRAY's PB Ratio is ranked higher than
69% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. XRAY: 2.07 )
Ranked among companies with meaningful PB Ratio only.
XRAY' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.69 Max: 4.65
Current: 2.07
1.58
4.65
PS Ratio 4.03
XRAY's PS Ratio is ranked lower than
53% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. XRAY: 4.03 )
Ranked among companies with meaningful PS Ratio only.
XRAY' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.41 Max: 4.03
Current: 4.03
1.58
4.03
Price-to-Free-Cash-Flow 35.44
XRAY's Price-to-Free-Cash-Flow is ranked lower than
57% of the 72 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.99 vs. XRAY: 35.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
XRAY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 19.74 Max: 35.44
Current: 35.44
12.38
35.44
Price-to-Operating-Cash-Flow 26.41
XRAY's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. XRAY: 26.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
XRAY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.42  Med: 15.35 Max: 26.51
Current: 26.41
10.42
26.51
EV-to-EBIT -23.29
XRAY's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. XRAY: -23.29 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.6  Med: 18.5 Max: 39.2
Current: -23.29
-23.6
39.2
EV-to-EBITDA -40.82
XRAY's EV-to-EBITDA is ranked lower than
99.99% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. XRAY: -40.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.4  Med: 14.5 Max: 27.1
Current: -40.82
-41.4
27.1
EV-to-Revenue 4.30
XRAY's EV-to-Revenue is ranked lower than
52% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. XRAY: 4.30 )
Ranked among companies with meaningful EV-to-Revenue only.
XRAY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 2.8 Max: 5.2
Current: 4.3
1.7
5.2
Shiller PE Ratio 43.25
XRAY's Shiller PE Ratio is ranked higher than
61% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.91 vs. XRAY: 43.25 )
Ranked among companies with meaningful Shiller PE Ratio only.
XRAY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.96  Med: 25.67 Max: 44.86
Current: 43.25
17.96
44.86
Current Ratio 2.32
XRAY's Current Ratio is ranked lower than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. XRAY: 2.32 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.89 Max: 4.36
Current: 2.32
1.2
4.36
Quick Ratio 1.59
XRAY's Quick Ratio is ranked lower than
59% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. XRAY: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.07 Max: 2.98
Current: 1.59
0.63
2.98
Days Inventory 118.47
XRAY's Days Inventory is ranked higher than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. XRAY: 118.47 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 89.71  Med: 101.08 Max: 118.47
Current: 118.47
89.71
118.47
Days Sales Outstanding 68.75
XRAY's Days Sales Outstanding is ranked lower than
56% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. XRAY: 68.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.12  Med: 56.27 Max: 68.75
Current: 68.75
53.12
68.75
Days Payable 51.57
XRAY's Days Payable is ranked lower than
51% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. XRAY: 51.57 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 37.45 Max: 51.57
Current: 51.57
31.01
51.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.50
XRAY's Dividend Yield % is ranked lower than
77% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.32 vs. XRAY: 0.50 )
Ranked among companies with meaningful Dividend Yield % only.
XRAY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.54 Max: 0.85
Current: 0.5
0.35
0.85
3-Year Dividend Growth Rate 7.40
XRAY's 3-Year Dividend Growth Rate is ranked lower than
55% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. XRAY: 7.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
XRAY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.6 Max: 37.5
Current: 7.4
0
37.5
Forward Dividend Yield % 0.52
XRAY's Forward Dividend Yield % is ranked lower than
79% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.32 vs. XRAY: 0.52 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.78
XRAY's 5-Year Yield-on-Cost % is ranked lower than
70% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. XRAY: 0.78 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XRAY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.53  Med: 0.82 Max: 1.3
Current: 0.78
0.53
1.3
3-Year Average Share Buyback Ratio -17.40
XRAY's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. XRAY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: 0.3 Max: 2.2
Current: -17.4
-67.6
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.64
XRAY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. XRAY: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
XRAY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.49 Max: 7.53
Current: 1.64
0.99
7.53
Price-to-Median-PS-Value 1.68
XRAY's Price-to-Median-PS-Value is ranked lower than
73% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. XRAY: 1.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XRAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.88 Max: 1.68
Current: 1.68
0.36
1.68
Earnings Yield (Greenblatt) % -4.29
XRAY's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. XRAY: -4.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XRAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.2  Med: 5.3 Max: 10.4
Current: -4.29
-5.2
10.4
Forward Rate of Return (Yacktman) % 4.64
XRAY's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.48 vs. XRAY: 4.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
XRAY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 10.3 Max: 31.1
Current: 4.64
-2
31.1

More Statistics

Revenue (TTM) (Mil) $3,898.90
EPS (TTM) $ -3.47
Beta1.41
Short Percentage of Float3.55%
52-Week Range $52.54 - 67.95
Shares Outstanding (Mil)229.68

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,971 4,158 4,375
EPS ($) 2.67 2.98 3.29
EPS without NRI ($) 2.67 2.98 3.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.47%
Dividends per Share ($) 0.33 0.33 0.39

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}